Clinical trial aimed at new therapeutic strategy for HAM by prosultiamine treatment with oral administration

Clinical trial aimed at new therapeutic strategy for HAM by prosultiamine treatment with oral administration - Oral prosultiamine treatment against HAM patients as new therapeutics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005969

Enrollment

Registered

2011-07-15

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HTLV-I associated myelopathy (HAM)

Interventions

Oral administration of prosultiamine at dosages of 300mg daily for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HAM patients who fulfilled the criteria of WHO

Exclusion criteria

Exclusion criteria: HAM patients who do not approve the protocol

Design outcomes

Primary

Measure	Time frame
The improvement of neurological signs including motor disability score and urinary disturbance with the decrease of HTLV-I-infected cells in the peripheral blood at 12 weeks after commencement.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026